Hyperfine (NASDAQ:HYPR) vs. Electromed (NYSE:ELMD) Financial Analysis

Hyperfine (NASDAQ:HYPR – Get Rating) and Electromed (NYSE:ELMD – Get Rating) are both small-cap medical…

Hyperfine (NASDAQ:HYPRGet Rating) and Electromed (NYSE:ELMDGet Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.


This table compares Hyperfine and Electromed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hyperfine N/A -60.78% -13.81%
Electromed 4.94% 5.77% 5.06%

Institutional and Insider Ownership

95.9% of Hyperfine shares are owned by institutional investors. Comparatively, 39.3% of Electromed shares are owned by institutional investors. 26.7% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Hyperfine and Electromed, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine 0 0 1 0 3.00
Electromed 0 0 0 0 N/A

Hyperfine currently has a consensus price target of $8.00, suggesting a potential upside of 122.84%. Given Hyperfine’s higher possible upside, equities analysts plainly believe Hyperfine is more favorable than Electromed.

Valuation and Earnings

This table compares Hyperfine and Electromed’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hyperfine $1.50 million 168.32 -$64.85 million N/A N/A
Electromed $35.76 million 3.04 $2.36 million $0.22 57.96

Electromed has higher revenue and earnings than Hyperfine.

Risk and Volatility

Hyperfine has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.


Electromed beats Hyperfine on 6 of the 11 factors compared between the two stocks.

Hyperfine Company Profile (Get Rating)

Hyperfine Inc. is a groundbreaking medical device company which created Swoop(R), first FDA-cleared portable MRI system(TM). Hyperfine Inc., formerly known as HealthCor Catalio Acquisition Corp., is based in GUILFORD, Conn.

Electromed Company Profile (Get Rating)

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Receive News & Ratings for Hyperfine Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hyperfine and related companies with MarketBeat.com’s FREE daily email newsletter.